<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) May 9, 2000
--------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
- ------------------------------- ----------- -----------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) file No.)
137 Newbury Street
8th Floor
Boston, Massachusetts 02116
- --------------------------------------- ------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
-----------------
<PAGE>
Item 5. Other Events.
-------------
On May 9, 2000, the Company announced that trading of the Company's stock would
move from the Nasdaq SmallCap Market to the Nasdaq National Market effective
with the market's opening on Wednesday, May 10. The stock will continue to
trade under the symbol BLSI.
Item 7. Exhibits.
---------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated May 9, 2000.
1
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: May 22, 2000 By: /s/Joseph Hernon
-----------------------
Joseph Hernon
Chief Financial Officer
2
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- --------------- --------
99.1 Press Release, dated May 9, 2000 4
3
<PAGE>
Exhibit 99.1
BOSTON LIFE SCIENCES, INC. TO COMMENCE TRADING ON NASDAQ NATIONAL MARKET
May 9, 2000--Boston, MA--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced
that trading of the Company's stock will move from the Nasdaq SmallCap Market to
the Nasdaq National Market effective with the market's opening on Wednesday, May
10. The stock will continue to trade under the symbol BLSI.
"Our ability to meet the strict listing requirements of the Nasdaq National
Market is a positive reflection of the Company's solid financial position and
increased market valuation. It is widely acknowledged that companies listed on
the National Market receive greater coverage and visibility in the financial
press and the investment community. Many institutional investors who have
recognized the value of our maturing technology portfolio have been previously
unable to take a position in BLSI stock. We believe that a National Market
listing will result in increased institutional ownership and greater market
recognition of BLSI, " commented David Hillson, President and CEO of BLSI.
BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease
(PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments
for cancer, autoimmune disease, and central nervous system disorders. BLSI's
products in development include: Altropane, a radioimaging agent for the
diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis
factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors
for the treatment of acute and chronic CNS disorders; fusion toxins for the
treatment of cancer and multiple sclerosis; novel therapies for the treatment of
PD and ADHD; and transcription factors that may control the expression of
molecules associated with autoimmune disease and allergies.
Statements made in this press release other than statements of historical fact
represent forward-looking statements. Such statements include, without
limitation, statements regarding expectations or beliefs as to future results or
events, such as the expected timing and results of clinical trials, discussions
with regulatory agencies, schedules of IND, NDA and all other regulatory
submissions, the timing of product introductions, the possible approval of
products, and the market size and possible advantages of the Company's products.
All such forward-looking statements involve substantial risks and uncertainties,
and actual results may vary materially from these statements. Factors that may
affect future results include: the availability and adequacy of financial
resources, the ability to obtain intellectual property protection, delays in the
regulatory or development processes, results of scientific data from clinical
trials, the outcome of discussions with potential partners, regulatory
decisions, market acceptance of the Company's products, and other possible risks
and uncertainties that have been noted in reports filed by the Company with the
Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K.
- --------------------------------------------------------------------------------
For further information, please contact:
<TABLE>
<CAPTION>
Investors Corporate Media
<S> <C> <C> <C>
Maria Zapf Brandon Lewis Boston Life Sciences, Inc. Jim Weinrebe
Boston Life Sciences, Inc. The Trout Group Marc Lanser, MD Schwartz Communications
617.425.0200, ext.17 212.477.9007, ext. 15 Chief Scientific Officer 781.684.0770
www.bostonlifesciences.com www.troutgroup.com 617.425.0200 www.schwartz-pr.com
</TABLE>
